Table 1.
| Hallmarks of Cancer | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adhesionc | Programed cell death | Cell Proliferation | Cell migration | Angiogenesis | Invasion | Metastasis | Epithelial to Messenchymal Transition | Cancer Progression | ||||||
| Higher Expression in MCF10CA1 | ||||||||||||||
| Accession Number | Gene name | Protein Name | MCF10Ab | MCF10Ab | MCF10CA1b | |||||||||
| P13728 | F3 | Tissue factor | 5 | 35 | 138 | x | x | x | x | x | ||||
| P42892 | ECE1 | Endothelin-converting enzyme 1 | 1 | 11 | 64 | x | ||||||||
| P13888 | CEACAM1 | Carcinoeembryonic antigen-related cell adhesion molecule 1 | 2 | 24 | 63 | x | ||||||||
| P08582 | MFI2 | Melanotransform | 1 | 12 | 61 | x | x | x | x | |||||
| P18084 | ITGB5 | Integrin beta-5 | 8 | 16 | 59 | x | x | x | x | |||||
| P08731 | CEACAM5 | Carcinoembryonic antigen-related cell adhesion molecule 5 | 0 | 0 | 54 | x | x | x | x | |||||
| Q9UBG0 | MRC2 | C-type mannose receptor 2 | 6 | 18 | 46 | x | x | x | ||||||
| P80188 | LCN2 | Neutrophil gelatinase-associated lipocalin (Lipocaln 2) | 7 | 0 | 43 | x | x | x | x | x | x | |||
| Q14672 | ADAM10 | Disintegrin and metalloproteinase domain-containing protein 10 | 6 | 18 | 36 | x | x | x | ||||||
| Q10589 | BST2 | Bone marrow stromal antigen 2 | 5 | 0 | 34 | x | x | x | x | |||||
| P08138 | NGFR | Tumor necrosis factor receptor superfamily member 16 | 0 | 0 | 28 | x | x | |||||||
| Q43653 | PSCA | Prostate stem cell antigen | 3 | 0 | 27 | |||||||||
| Q12805 | EFEMP1 | EGF-containing fibulin-like extracellular matrix protein 1 | 2 | 2 | 26 | x | x | |||||||
| P20061 | TCN1 | Transcobalamin-1 | 0 | 2 | 26 | |||||||||
| P15151 | PVR | Poliovirus receptor | 5 | 11 | 25 | x | x | x | ||||||
| Q00488 | AGRN | Agrin | 2 | 3 | 24 | |||||||||
| QBNBJ4 | G0LM1 | Golgi membrane protein 1 | 3 | 8 | 23 | |||||||||
| Q03405 | PLAUR | Urokinase plasminogen activator surface receptor | 5 | 11 | 23 | x | ||||||||
| Q04900 | CD164 | Sialomucin core protein 24 | 0 | 0 | 18 | x | x | x | ||||||
| Q8Y337 | KLK5 | Kallikrein-5 | 0 | 1 | 15 | |||||||||
| Q6UXD5 | SEZ0L2 | Seizure 6-like protein 2 | 0 | 3 | 11 | |||||||||
| Q88715 | COL12A1 | Collagen alpha-1(XII) chain | 0 | 3 | 8 | x | ||||||||
| Higher Expression in MCF10AT and MCF10CA1a | ||||||||||||||
| Accession Number | Protein Name | MCF10A | MCFCAT | MCF10CA1 | ||||||||||
| O95274 | LYPD3 | Ly6/PLAUR domain-containing protein 3 | 3 | 81 | 125 | x | x | |||||||
| P185S4 | ITGB6 | Integrin beta-6 | 5 | 59 | 76 | x | ||||||||
| O43278 | SPINT1 | Kunitz-type protease inhibitor 1 | 6 | 34 | 60 | x | x | x | ||||||
| P48960 | CD87 | CD87 antigen | 5 | 27 | 28 | x | ||||||||
| Q8N271 | PROM2 | Prominin-2 | 0 | 29 | 21 | |||||||||
| Q92692 | PVRL2 | Poliovirus receptor-related protein 2 | 2 | 13 | 21 | x | ||||||||
| Q60449 | LY75 | Lymphocyte antigen 75 | 0 | 15 | 17 | |||||||||
| O15031 | PLXNB2 | Plexin B-2 | 2 | 9 | 14 | |||||||||
| P00533 | EGFR | Epidermal growth factor receptor | 0 | 9 | 13 | x | x | x | ||||||
| Q16790 | CA9 | Carbonic anhydrase 9 | 0 | 7 | 11 | x | ||||||||
| P19256 | CD58 | Lymphocyte function-associated antigen 3 | 0 | 6 | 9 | x | ||||||||
| Lower Expression in either MCF10AT and/or MCF10CA1 | ||||||||||||||
| Accession Number | Protein Name | MCF10A | MCF10AT | MCF10CA1 | ||||||||||
| P08571 | CD14 | Monocyte differentiation antigen CD14 | 29 | 6 | 0 | |||||||||
| P05362 | ICAM1 | Intercellular adhesion molecule 1 | 21 | 0 | 0 | x | x | x | ||||||
| Q9H3G5 | CPVL | Probable serine carboxypeptidase CPVL | 14 | 0 | 0 | |||||||||
| Q9UQC9 | CLCA2 | calcium-activated chloride channel regulator 2 | 14 | 12 | 0 | x | x | |||||||
| PGM73 | HME | Nepriysin | 9 | 0 | 0 | x | ||||||||
a
Identified by Significance analysis for microarrays (SAM) program
b
Average spectral counts from four biological replicates.
c
An X indicates that the glycoprotein has been associated with the specific hallmark of cancer.